Lataa...
"Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer
BACKGROUND: In a significant proportion of metastatic breast cancer (MBC) patients whose tumour has progressed within 6 months of endocrine therapy (de novo resistance), it is generally believed that the chance of achieving clinical benefit (CB) with further endocrine therapy is minimal. METHODS: Da...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2006
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1538598/ https://ncbi.nlm.nih.gov/pubmed/16822312 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1477-7819-4-40 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|